Proteins and Peptides

22 Apr 2017 BioMarin Receives Positive CHMP Opinion in Europe for Brineura™ (cerliponase alfa) for First Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare and Fatal Brain Disorder in Children
22 Apr 2017 NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
22 Apr 2017 Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
20 Apr 2017 First Patient in Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET
20 Apr 2017 ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema
18 Apr 2017 Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
18 Apr 2017 BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
18 Apr 2017 Spero Therapeutics Highlights Potentiator Program Data at the 27th European Congress of Clinical Microbiology and Infectious Diseases
14 Apr 2017 Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial
12 Apr 2017 Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
11 Apr 2017 Audax Medical, Inc. Licenses Novel Self-Assembling Nanomolecule from Northeastern University for Development of Tissue Regenerative Products
10 Apr 2017 Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B
06 Apr 2017 Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)
06 Apr 2017 XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome
04 Apr 2017 ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
04 Apr 2017 Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
04 Apr 2017 amcure Presents Preclinical Data on Lead Cancer Compound AMC303 at AACR Annual Meeting
03 Apr 2017 Versartis Reports New Data on Long-Acting Somavaratan in Growth Hormone Deficiency at ENDO 2017
03 Apr 2017 Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017
03 Apr 2017 Teva Receives Positive Outcome for COPAXONE® 40 mg/ml 3 Times Weekly Label in Europe
03 Apr 2017 Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
01 Apr 2017 Halozyme Provides Update On SWOG Collaborative Group Clinical Study
30 Mar 2017 ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
29 Mar 2017 ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer
29 Mar 2017 Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing